With Arbor Biotechnologies unveiling FDA approval of an IND filing for their LNP-mediated treatment for primary hyperoxaluria type 1, LNPs continue to be the hottest delivery vehicle across all payload types and completely dominate the non-viral delivery field, the promise of this delivery vehicle is truly ground-breaking!

Landing at The Westin Copley Place in Boston, the 4th LNP Formulation & Process Development Summit returns as the only industry summit dedicated to navigating LNP bottlenecks of designing novel ionizable lipids, achieving extrahepatic delivery, improving thermostability and accomplishing large scale manufacturing for advancing LNPS for a variety of applications towards the patients in need.

With a revamped track design, the 2025 meeting has 3 dedicated streams Analytical Development & Characterization, Formulation & Delivery and Process Development & Manufacturing to deep dive into an end-to-end strategy for revolutionizing the discovery and development of potent, safe and stable LNPs for targeted delivery of cell therapies, gene therapies, mRNA therapeutics and beyond!

Uniting 230+ LNP trailblazers from across the globe, this is your one-stop-shop for LNP specific networking, partnership opportunities and collaborative discussions to further fuel advancement of LNPs towards clinical development.

Event link here.